Side-by-side comparison of AI visibility scores, market position, and capabilities
Rare disease biotech developing polytherapy approach for Rett Syndrome (1 in 10,000 girls); founder-developed protocol validated through personal patient experience competing with Acadia Pharmaceuticals Daybue in Rett market.
Uncommon Therapeutics is a biotech company founded by Noah Auerhahn — directly inspired by his daughter's diagnosis with Rett Syndrome, a severe genetic neurological disease affecting approximately 1 in 10,000 girls — applying a polytherapy approach (combining multiple therapeutic agents targeting different disease mechanisms simultaneously) to develop treatments for serious neurological and rare diseases. After improving his daughter's quality of life through a personally developed polytherapy protocol, Auerhahn founded Uncommon Therapeutics to translate these insights into pharmaceutical products for the broader Rett Syndrome patient community.
UK private chef marketplace with 900+ chefs and $6.7M annualized revenue; 45-65% word-of-mouth growth backed by YC and Goodwater Capital expanding to US in 2025.
yhangry is a London-based marketplace connecting customers with 900+ private chefs for in-home dining experiences — enabling individuals, couples, and groups to book a professional chef who shops for ingredients, cooks a multi-course meal in the customer's kitchen, and handles cleanup, for occasions ranging from date nights to dinner parties and corporate events. Founded in 2022 and backed by Y Combinator, Goodwater Capital, and prominent angels with $3.5 million raised, yhangry achieved $6.7 million in annualized revenue in 2024 with 5,300+ bookings and prepares for US expansion in 2025.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.